• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JANUARY 25, 2001

Higher tax outgo suppresses Nicholas' 3Q net

Nicholas Piramal has declared a 17.6% growth in turnover for the third quarter ended December 2001. The growth in turnover is on the back of a 7% growth in the two products Haemaccel and Omnatax that the company took over from Hoechst last year. Though the pre–tax margins of Nicholas have jumped 14.8%, a higher tax outgo has only led to a 5.7% growth in the post tax profits.

(Rs m) 3QFY00 3QFY01 Change
Sales 1,127 1,325 17.6%
Other Income 19 19 1.0%
Expenditure 961 1,128 17.3%
Operating Profit (EBDIT) 166 197 19.0%
Operating Profit Margin (%) 14.7% 14.9%  
Interest 30 34  
Depreciation 28 36 28.7%
Profit before Tax 127 146 14.8%
Other Adjustments   -  
Tax 15 27 83.9%
Profit after Tax/(Loss) 112 119 5.7%
Net profit margin (%) 10.0% 9.0%  
Earnings per share* 16.23 17.15  

The company has already introduced 'Aablaquin' its anti–malarial product and 'Rejoint' (a nutraceutical for osteoporosis) in the previous quarter. While 'Aabalaquin' can be expected to contribute substantially to the company's turnover in the coming two quarters during the summer months when the outbreak of malaria is at its peak, 'Rejoint' has received a good reception. The company's anti–infective products have however stagnated.

The stock quotes at a price of Rs 355 which implies an earnings multiple of 21 times 3QFY01 annualised earnings.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407